- Fmoc-Asp(OtBu)-OH
-
- $0.00 / 25Kg/Drum
-
2025-09-29
- CAS:71989-14-5
- Min. Order: 1KG
- Purity: 98%min
- Supply Ability: 1000kg
|
| | Fmoc-Asp(OtBu)-OH Basic information |
| | Fmoc-Asp(OtBu)-OH Chemical Properties |
| Melting point | 148-150 °C (dec.) | | alpha | -25 º (c=1,DMF 24 ºC) | | Boiling point | 530.45°C (rough estimate) | | density | 1.2498 (rough estimate) | | refractive index | -25 ° (C=1, DMF) | | storage temp. | 2-8°C | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | pka | 3.57±0.23(Predicted) | | form | powder to crystal | | color | White to Almost white | | Optical Rotation | [α]20/D 24±2°, c = 1% in DMF | | Water Solubility | Slightly soluble in water. | | BRN | 3635671 | | InChIKey | FODJWPHPWBKDON-IBGZPJMESA-N | | CAS DataBase Reference | 71989-14-5(CAS DataBase Reference) |
| | Fmoc-Asp(OtBu)-OH Usage And Synthesis |
| Chemical Properties | Fmoc-Asp(OtBu)-OH is a protected form of L-aspartic acid. It is a white to light yellow crystal powder. The molecule contains ester groups and amino groups, making it prone to polymerization and unstable over time. Therefore, it is not recommended to store it for extended periods. | | Uses | L-Aspartic acid is a nonessential amino acid that is used to biosynthesize other amino acids within the human body. | | Preparation | Fmoc-Asp(OtBu)-OH was prepared by substitution reaction with 9-fluorenylmethyl chloroformate from L-aspartic acid 4-tert-butyl ester. | | General Description |
Fmoc-Asp(OtBu)-OH is a white to off-white solid, it can be used for peptide synthesis.
| | reaction suitability | reaction type: Fmoc solid-phase peptide synthesis | | Synthesis | The general procedure for the synthesis of Fmoc-L-aspartic acid β-tert-butyl ester from the compound (CAS:144120-52-5) was as follows: firstly, PdEnCat 30 (Aldrich; loading 0.4 mmol/g, use 0.05 eq.) was suspended in THF-H2O (9:1 v/v, total 5 mL) and treated with argon bubbling for 10 min for deoxygenation. Subsequently, DCHT (0.15 eq.) and the corresponding ester 1 (1.0 eq., 70 mg) were added under positive pressure. Finally, PhSiH3 (2.0 eq.) was injected and the reaction mixture was allowed to react at room temperature for 2 h. The reaction was carried out under low pressure. After completion of the reaction, the mixture was filtered through Celite and the filtrate was concentrated under reduced pressure. The residual solid was dissolved with EtOAc (20 mL) and washed sequentially with H2O (3 x 10 mL) and brine (3 x 10 mL). The organic layer was dried over MgSO4 and concentrated in vacuum. Purification was carried out by solid phase extraction (using C18 reversed-phase chromatography with H2O/MeOH as eluent) to obtain pure carboxylic acid 2 (see Table 1 for yields). The purity of the products was confirmed analytically by HPLC, 1H NMR and 13C NMR. All the carboxylic acids were commercially available. The 1H and 13C NMR spectra of the synthesized compounds were in agreement with those of commercial samples. | | References | [1] Synlett, 2014, vol. 25, # 16, p. 2319 - 2322 |
| | Fmoc-Asp(OtBu)-OH Preparation Products And Raw materials |
| Raw materials | tert-Butyl acetate-->L-ASPARTIC ACID-->L-Aspartic acid 4-tert-butyl ester-->9-Fluorenylmethyl chloroformate-->L-Aspartic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 4-(1,1-dimethylethyl) 1-(2-propen-1-yl) ester-->2-(DICYCLOHEXYLPHOSPHINOETHYL)TRIMETHYLAMMONIUM CHLORIDE-->Water-->Tetrahydrofuran-->Phenylsilane | | Preparation Products | FMOC-ASPARTIMOL(OTBU)-->ANGIOTENSIN I, HUMAN-->CYCLO (ARG-GLY-ASP-D-PHE-LYS)-->(R)-(-)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate-->L-Aspartic acid-->ANGIOTENSIN II, HUMAN-->FMOC-ASP(OBUT)-NH2 |
|